The advantage of this drug delivery system is the ability to directly target specific skeletal sites of disease, while also being able to administer the lowest, clinically effective dose possible, thereby lowering the potential for harmful side effec

Summary

Current technologies for the treatment of cancer bone metastasis involve non-specific administering drugs at their free form. To be able to reach bone lesions through systemic administration, the drug concentration usually should be administered at its highest allowed concentration for prolonged period of time, which significantly increases treatment side effects. Researchers at the University of Nebraska Medical Center have developed a novel drug delivery system, which upon the administration directly reached and specifically binds to bones. Since the drugs are directly delivered to the bone, the toxic side effects of devastating cancer chemotherapy side effects are significantly reduced and lower drug concentrations can be used. In addition the novel technology allows manipulation with the degree of binding of delivery system to a bone tissue. This adds additional advantage of controlling the kinetics of distribution of drug in the body.

Market Value

One of the major problems with drug treatments for bone cancer and other bone diseases is drug treatments must be administered nonspecifically and at very high doses. This is problematic because these drugs come in contact with nearly every tissue in the body, often exerting toxic side effects. The advantage of this drug delivery system is the ability to directly target specific skeletal sites of disease, while also being able to administer the lowest, clinically effective dose possible, thereby lowering the potential for harmful side effects.

Features & Benefits

• Specific drug delivery system bone diseases
• Significantly decreases toxicity of treatments
• System of delivery can be easily manipulated to vary degree of bone-binding

Early Stage

TID 132

UNeMed Corporation offers a variety of licensing options and collaborative development opportunities with the University of Nebraska Medical Center.